{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:31:32Z","timestamp":1787992292030,"version":"build-2784847793"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The past decade has seen an increased delivery of cardiac resynchronization therapy (CRT) for patients with heart failure (HF). We explored whether clinical outcomes after CRT have changed from the perspective of an entire public healthcare system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A national database covering the population of England (56.3 million in 2019) was used to explore clinical outcomes after CRT from 2010 to 2019. A total of 64 698 consecutive patients (age 71.4 \u00b1 11.7 years; 74.8% male) underwent CRT-defibrillation [n = 32 313 (49.7%)] or CRT-pacing [n = 32 655 (50.3%)] implantation. From 2010\u20132011 to 2018\u20132019, there was a 76% increase in CRT implantations. During the same period, the proportion of patients with hypertension (59.6\u201373.4%), diabetes (26.5\u201330.8%), and chronic kidney disease (8.62\u201322.5%) increased, as did the Charlson comorbidity index (CCI \u2265 3 from 20.0% to 25.1%) (all P &amp;lt; 0.001). Total mortality decreased at 30 days (1.43\u20131.09%) and 1 year (9.51\u20138.13%) after implantation (both P &amp;lt; 0.001). At 2 years, total mortality [hazard ratio (HR): 0.72; 95% confidence interval (CI) 0.69\u20130.76] and total mortality or HF hospitalization (HR: 0.59; 95% CI 0.57\u20130.62) decreased from 2010\u20132011 to 2018\u20132019, after correction for age, race, sex, device type (CRT-defibrillation or pacing), comorbidities (hypertension, diabetes, chronic kidney disease, and myocardial infarction), or the CCI (HR: 0.81; 95% CI 0.77\u20130.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>From the perspective of an entire public health system, survival has improved and HF hospitalizations have decreased after CRT implantation over the past decade. This prognostic improvement has occurred despite an increasing comorbidity burden.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad141","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T22:04:17Z","timestamp":1685743457000},"source":"Crossref","is-referenced-by-count":23,"title":["Improved prognosis after cardiac resynchronization therapy over a decade"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2176-0223","authenticated-orcid":false,"given":"Francisco","family":"Leyva","sequence":"first","affiliation":[{"name":"Aston Medical Reseach Insitute, Aston Medical School, Aston University, Aston Triangle , Birmingham B4 7ET , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-7468","authenticated-orcid":false,"given":"Abbasin","family":"Zegard","sequence":"additional","affiliation":[{"name":"Aston Medical Reseach Insitute, Aston Medical School, Aston University, Aston Triangle , Birmingham B4 7ET , UK"},{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peysh","family":"Patel","sequence":"additional","affiliation":[{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-8022","authenticated-orcid":false,"given":"Berthold","family":"Stegemann","sequence":"additional","affiliation":[{"name":"Aston Medical Reseach Insitute, Aston Medical School, Aston University, Aston Triangle , Birmingham B4 7ET , UK"},{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5558-5358","authenticated-orcid":false,"given":"Howard","family":"Marshall","sequence":"additional","affiliation":[{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7237-0946","authenticated-orcid":false,"given":"Peter","family":"Ludman","sequence":"additional","affiliation":[{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-2074","authenticated-orcid":false,"given":"Joseph","family":"de Bono","sequence":"additional","affiliation":[{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9820-4815","authenticated-orcid":false,"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"Cardiology Division, Department of Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena , Via Universita 4, Modena 41100 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Qiu","sequence":"additional","affiliation":[{"name":"Univeristy Hospitals Birmingham Queen Elizabeth, Mindelsohn Way , Birmingham B15 2WB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2023060211422898500_euad141-B1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2014.06.1178","article-title":"20 years of cardiac resynchronization therapy","volume":"64","author":"Leyva","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2023060211422898500_euad141-B2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman","year":"2016","journal-title":"N Eng J Med"},{"key":"2023060211422898500_euad141-B3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jama.2017.9991","article-title":"Multidimensional evidence generation and FDA regulatory decision making: defining and using \u201creal-world\u201d data","volume":"318","author":"Jarow","year":"2017","journal-title":"JAMA"},{"key":"2023060211422898500_euad141-B4","author":"US Food and Drug Administration"},{"key":"2023060211422898500_euad141-B5","author":"National Institute for Health and Care Excellence"},{"key":"2023060211422898500_euad141-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.hroo.2022.03.004","article-title":"Temporal trends and long-term outcomes among recipients of cardiac resynchronization therapy with defibrillator in the United States, 2011\u20132015: insights from the National Cardiovascular Data Registry","volume":"3","author":"Darden","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"2023060211422898500_euad141-B7","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/europace\/eus256","article-title":"The EHRA white book","volume":"14","author":"Arribas","year":"2012","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B8","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/europace\/euab123","article-title":"The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy","volume":"23","author":"Varma","year":"2021","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023060211422898500_euad141-B10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/ejhf.1142","article-title":"CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients-who is doing what to whom and how?","volume":"20","author":"Dickstein","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2023060211422898500_euad141-B11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007026","article-title":"Cardiac resynchronization therapy using quadripolar versus non-quadripolar left ventricular leads programmed to biventricular pacing with single-site left ventricular pacing: impact on survival and heart failure hospitalization","volume":"6","author":"Leyva","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023060211422898500_euad141-B12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/europace\/euz196","article-title":"Clinical outcomes after implantation of quadripolar compared to bipolar left ventricular leads in patients undergoing cardiac resynchronization therapy: a systematic review and meta-analysis","volume":"21","author":"Erath","year":"2019","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Eng J Med"},{"key":"2023060211422898500_euad141-B14","first-page":"1","article-title":"Timing of cardiac resynchronization therapy implantation","author":"Leyva","year":"2023","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B15","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/hrt.2010.209171","article-title":"The national heart failure audit for England and Wales 2008-2009","volume":"97","author":"Cleland","year":"2011","journal-title":"Heart"},{"key":"2023060211422898500_euad141-B16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/europace\/eut206","article-title":"2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)","volume":"15","author":"Brignole","year":"2013","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/europace\/euab232","article-title":"2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"24","author":"Glikson","year":"2022","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.amjcard.2007.10.048","article-title":"Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation","volume":"101","author":"Thibodeau","year":"2008","journal-title":"Am J Cardiol"},{"key":"2023060211422898500_euad141-B19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/01.CIR.0000080290.39027.48","article-title":"Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared with other specialists","volume":"108","author":"Jong","year":"2003","journal-title":"Circulation"},{"key":"2023060211422898500_euad141-B20","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/europace\/euy267","article-title":"Survival after cardiac resynchronization therapy: results from 50 084 implantations","volume":"21","author":"Leyva","year":"2019","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/europace\/euq328","article-title":"The prognosis of implantable defibrillator patients treated with cardiac resynchronization therapy: comorbidity burden as predictor of mortality","volume":"13","author":"Theuns","year":"2011","journal-title":"Europace"},{"key":"2023060211422898500_euad141-B22","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.amjcard.2017.06.056","article-title":"Impact of an age-adjusted co-morbidity index on survival of patients with heart failure implanted with cardiac resynchronization therapy devices","volume":"120","author":"Ioannou","year":"2017","journal-title":"Am J Cardiol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/6\/euad141\/50509915\/euad141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/6\/euad141\/50509915\/euad141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T22:04:28Z","timestamp":1685743468000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad141\/7188948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad141","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,6]]},"article-number":"euad141"}}